SEC Tracker
Get the app

Imunon IMNN

Imunon FY 2023: net loss $19.5M; diluted EPS −$2.16

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Imunon reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$19.5MAgainst −$35.9M in FY 202210-K income statement, on EDGAR
  2. Diluted EPS−$2.16Against −$5.03 in FY 202210-K income statement, on EDGAR
  3. Cash and cash equivalents$5.8M−49% from $11.5M in FY 2022Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
  4. Cash from operations−$19.0MAgainst −$23.1M in FY 202210-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Imunon files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Armata Pharmaceuticals ARMP public float $21M, Jun 30, 2025
  2. Lunai Bioworks LNAI public float $21M, Dec 31, 2025
  3. Dare Bioscience DARE public float $21M, Jun 30, 2025
  4. Fibrogen FGEN public float $21M, Jun 30, 2025
  5. Aptose Biosciences APTOF public float $22M, Jun 28, 2025